If you have any question, please feel free to email us. We will touch with you as soon as possible.
CAS:82159-09-9
Source:India
Qualifications:-/-/-/-/-
| Name | Epalrestat |
|---|---|
| Chinese name | 依帕司他 |
| Cas Number | 82159-09-9 |
| Source | India |
| Qualifications | -/-/-/-/- |
Epalrestat is the only non-competitive reversible aldose reductase inhibitor currently on the market. It is suitable for diabetic neuropathy. It was developed by Japan's Ono Pharmaceutical and was first marketed in Japan in 1992. Epalrestat is a reversible non-competitive inhibitor of aldose reductase. Aldose reductase is mainly distributed in peripheral nerves, retina, lens, kidney and other parts of the body. Epalrestat can effectively inhibit aldose reductase. Active, early intervention, block polyol pathway, and play an active role in the prevention and treatment of chronic complications of diabetes. The mechanism of action of epalrestat is aimed at the pathogenesis of diabetic neuropathy, and is the recommended drug for the treatment of neuropathy in the "Guidelines for Prevention and Treatment of Type II Diabetes in China".
Hot Tags: epalrestat api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Cinacalcet Hydrochloride API, Lifitegrast API, Brinzolamide API, Active Pharmaceutical Ingredient, Tippyridine Hydrochloride API, Bivalrudine API
Tel:+86-020-61855200-902
Fax:+86-020-66392525
Email:info@upharm.cn
Address:12th floor, No. 181, Kexue Avenue, Huangpu District, Guangzhou, China
